The effect of alendronate on the expression of important cell factors in osteoclasts

Zhang,Qinghong; Liu,Mengtao; Zhou,Yi; Liu,Wei; Shen,Juxiang; Shen,Yanqing; Liu,Li

doi:10.3892/mmr.2013.1630

The effect of alendronate on the expression of important cell factors in osteoclasts

Authors:
- Qinghong Zhang
- Mengtao Liu
- Yi Zhou
- Wei Liu
- Juxiang Shen
- Yanqing Shen
- Li Liu
View Affiliations

Affiliations: Department of Prosthodontics, Stomatology Hospital, College of Medical Sciences, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China, Department of Prosthodontics, Hengha Stomatology Hospital, Hangzhou, Zhejiang 310013, P.R. China
Published online on: August 14, 2013 https://doi.org/10.3892/mmr.2013.1630
Pages: 1195-1203

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated the effects of alendronate (ALN) on critical cell factors in osteoclasts. RAW 264.7 cells were induced by sRANKL to change to mature osteoclasts. On the sixth day of incubation, the osteoclasts were treated with ALN at various concentrations and for different incubation times. The concentration groups included 10-5 M, 10-6 M and 10-7 M ALN, respectively. The cells were incubated for 0 (control group), 2, 4, 6 and 8 h for each dose group. The mRNA and protein expression of tartrate‑resistant acid phosphatase, carbonic anhydrase II, osteoclast‑associated receptor and FAS/FASL genes in osteoclasts was analyzed. A concentration- and time‑dependent decrease in the mRNA and protein expression levels of the five genes was observed, and no significant difference between the two control groups was observed (P>0.05). Notably, significant differences between any two experimental groups were observed (P<0.05). Thus, ALN significantly decreased the expression of critical factors involved in osteoclast function.

View Figures

View References

1	Doody KM, Bussières-Marmen S, Li A, et al: T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice. Arthritis Rheum. 64:752–761. 2012. View Article : Google Scholar : PubMed/NCBI
2	Klijn RJ, van den Beucken JJ, Bronkhorst EM, et al: Predictive value of ridge dimensions on autologous bone graft resorption in staged maxillary sinus augmentation surgery using Cone-Beam CT. Clin Oral Implants Res. 23:409–415. 2012. View Article : Google Scholar
3	Nonaka CF, Cavalcante RB, Nogueira RL, et al: Immunohistochemical analysis of bone resorption regulators (RANKL and OPG), angiogenic index, and myofibroblasts in syndrome and non-syndrome odontogenic keratocysts. Arch Oral Biol. 57:230–237. 2012. View Article : Google Scholar
4	Hong ZQ, Tao LM and Li L: Effect of stress on mRNA expression of H⁺-ATPase in osteoclasts. Mol Cell Biochem. 343:183–190. 2010. View Article : Google Scholar : PubMed/NCBI
5	Nakayama T, Mizoguchi T, Uehara S, et al: Polarized osteoclasts put marks of tartrate-resistant acid phosphatase on dentin slices - a simple method for identifying polarized osteoclasts. Bone. 49:1331–1339. 2011. View Article : Google Scholar : PubMed/NCBI
6	Fujisaki K, Tanabe N, Suzuki N, et al: Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci. 80:1311–1318. 2007. View Article : Google Scholar : PubMed/NCBI
7	Zhang Q, Liang X, Zhu B, et al: Effects of fluid shear stress on mRNA expression of carbonic anhydrase II in polarized rat osteoclasts. Cell Biol Int. 30:714–720. 2006. View Article : Google Scholar : PubMed/NCBI
8	Goettsch C, Rauner M, Sinningen K, et al: The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. Endocrinology. 152:4915–4926. 2011. View Article : Google Scholar
9	Ishikawa S, Arase N, Suenaga T, et al: Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). Int Immunol. 16:1019–1025. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kim JH, Kim K, Jin HM, et al: Upstream stimulatory factors regulate OSCAR gene expression in RANKL-mediated osteoclast differentiation. J Mol Biol. 383:502–511. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kim JH, Kim K, Youn BU, et al: MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR. Cell Signal. 22:1341–1349. 2010. View Article : Google Scholar
12	Kovacić N, Lukić IK, Grcević D, et al: The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol. 178:3379–3389. 2007.PubMed/NCBI
13	Krum SA, Miranda-Carboni GA, Hauschka PV, et al: Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 27:535–545. 2008. View Article : Google Scholar : PubMed/NCBI
14	Nakamura T, Imai Y, Matsumoto T, et al: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 130:811–823. 2007. View Article : Google Scholar : PubMed/NCBI
15	Boanini E, Torricelli P, Gazzano M, et al: Alendronate-hydroxy- apatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials. 29:790–796. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kawata T, Tenjou K, Tokimasa C, et al: Effect of alendronate on osteoclast differentiation and bone volume in transplanted bone. Exp Anim. 53:47–51. 2004.PubMed/NCBI
17	Moon HJ, Yun YP, Han CW, et al: Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function. Biochem Biophys Res Commun. 413:194–200. 2011. View Article : Google Scholar
18	Panzavolta S, Torricelli P, Bracci B, et al: Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem. 103:101–106. 2009. View Article : Google Scholar : PubMed/NCBI
19	Rogers MJ, Frith JC, Luckman SP, et al: Molecular mechanisms of action of bisphosphonates. Bone. 24:73S–79S. 1999. View Article : Google Scholar
20	Sugata Y, Sotome S, Yuasa M, et al: Effects of the systemic administration of alendronate on bone formation in a porous hydroxyapatite/collagen composite and resorption by osteoclasts in a bone defect model in rabbits. J Bone Joint Surg Br. 93:510–516. 2011. View Article : Google Scholar
21	Sama AA, Khan SN, Myers ER, et al: High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin Orthop Relat Res. 425:135–142. 2004. View Article : Google Scholar : PubMed/NCBI
22	Koshihara Y, Kodama S, Ishibashi H, et al: Reversibility of alendronate-induced contraction in human osteoclast-like cells formed from bone marrow cells in culture. J Bone Miner Metab. 17:98–107. 1999. View Article : Google Scholar : PubMed/NCBI
23	Breuil V, Cosman F, Stein L, et al: Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res. 13:1721–1729. 1998. View Article : Google Scholar : PubMed/NCBI
24	Hong ZQ, Tao LM and Li L: mRNA expression in osteoclasts: a chronobiological approach. Biological Rhythm Research. 42:287–298. 2011. View Article : Google Scholar
25	D’Amelio P, Grimaldi A, Cristofaro MA, et al: Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 21:1741–1750. 2010.PubMed/NCBI
26	Fisher JE, Rogers MJ, Halasy JM, et al: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA. 96:133–138. 1999. View Article : Google Scholar
27	Sato M, Grasser W, Endo N, et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:2095–2105. 1991. View Article : Google Scholar : PubMed/NCBI
28	Owens JM, Fuller K and Chambers TJ: Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol. 172:79–86. 1997. View Article : Google Scholar : PubMed/NCBI
29	Zhang Q, Badell IR, Schwarz EM, et al: Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum. 52:2708–2718. 2005. View Article : Google Scholar : PubMed/NCBI
30	Wang XM, Yu SF and Yang ZP: Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. Chin J Dent Res. 3:26–32. 2000.PubMed/NCBI
31	Halasy-Nagy JM, Rodan GA and Reszka AA: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 29:553–559. 2001. View Article : Google Scholar : PubMed/NCBI
32	Alakangas A, Selander K, Mulari M, et al: Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int. 70:40–47. 2002. View Article : Google Scholar : PubMed/NCBI
33	Kum KY, Park JH, Yoo YJ, et al: The inhibitory effect of alendronate and taurine on osteoclast differentiation mediated by Porphyromonas gingivalis sonicates in vitro. J Endod. 29:28–30. 2003. View Article : Google Scholar
34	Colucci S, Minielli V, Zambonin G, et al: Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int. 63:230–235. 1998. View Article : Google Scholar : PubMed/NCBI
35	Schmidt A, Rutledge SJ, Endo N, et al: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci USA. 93:3068–3073. 1996. View Article : Google Scholar